Journal
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE
Volume 4, Issue 4, Pages 105-131Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2049936117713593
Keywords
advances; hepatitis; HIV; influenza; nanotechnology; vaccine; virus
Categories
Funding
- National Health Laboratory Service Research Trust [94503]
- National Research Foundation [99294]
Ask authors/readers for more resources
Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery. These are predominantly due to the particle size (which affects bioavailability and circulation time), large surface area to volume ratio (enhanced solubility compared to larger particles), tunable surface charge of the particle with the possibility of encapsulation, and large drug payloads that can be accommodated. These properties, which are unlike bulk materials of the same compositions, make nanoparticulate drug delivery systems ideal candidates to explore in order to achieve and/or improve therapeutic effects. This review presents a broad overview of the application of nanosized materials for the treatment of common viral infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available